Savka I. Stoeva

Novel two-component oligonucleotide-modified nanoparticle probes have been designed and used in a bio-bar-code assay with a 500 zeptomolar target DNA sensitivity limit.

We have developed the chemistry for preparing a universal probe and the appropriate nano- and microparticle labels that can be used to do highly selective multiplexed detection of three protein cancer markers at low-femtomolar concentration in buffer and serum media. The approach relies on a new multiplexed version of the biobarcode amplification method and offers new opportunities for studying multiple protein markers in a single sample. This could lead to new forms of disease diagnosis and monitoring disease recurrence in a variety of settings.

We report the development of a previously undescribed gold nanoparticle bio-barcode assay probe for the detection of prostate specific antigen (PSA) at 330 fg/mL, automation of the assay, and the results of a clinical pilot study designed to assess the ability of the assay to detect PSA in the serum of 18 men who have undergone radical prostatectomy for prostate cancer. Due to a lack of sensitivity, available PSA immunoassays are often not capable of detecting PSA in the serum of men after radical prostatectomy. This new bio-barcode PSA assay is approximately 300 times more sensitive than commercial immunoassays. Significantly, with the barcode assay, every patient in this cohort had a measurable serum PSA level after radical prostatectomy. Patients were separated into categories based on PSA levels as a function of time. One group of patients showed low levels of PSA with no significant increase with time and did not recur. Others showed, at some point postprostatectomy, rising PSA levels. The majority recurred. Therefore, this new ultrasensitive assay points to significant possible outcomes: (i) The ability to tell patients, who have undetectable PSA levels with conventional assays, but detectable and nonrising levels with the barcode assay, that their cancer will not recur. (ii) The ability to assign recurrence earlier because of the ability to measure increasing levels of PSA before conventional tools can make such assignments. (iii) The ability to use PSA levels that are not detectable with conventional assays to follow the response of patients to adjuvant or salvage therapies.

We describe a synthetic procedure for preparation of large quantities of monodisperse thiol-stabilized gold colloids in toluene solution. The method is based on the solvated metal atom dispersion technique (SMAD), which is very suitable for preparation of large amounts of metal colloidal solutions, as well as of metal sulfide, metal oxide, and other types of dispersed compounds in different solvents. A combination of two different solvents like acetone and toluene is used for the preparation of the gold colloids. The necessity of initially carrying out the SMAD reaction in acetone comes from its high degree of solvation of gold particles. Acetone acts as a preliminary stabilizing agent. After its removal from the system, the particles are stabilized by dodecanethiol molecules, which enable their very good dispersion in toluene solution. A digestive ripening procedure is carried out with the gold-toluene colloid, and for this purpose pure toluene as solvent is necessary. This has a dramatic effect on the narrowing of particle size distribution and almost monodisperse colloids are obtained (some discussion of the probable mechanism of this remarkable digestive ripening step is given). These colloidal solutions have a great tendency to organize in two- and three-dimensional structures (nanocrystal superlattices, NCSs). We believe that this procedure provides a real opportunity to synthesize large amounts of gold nanocrystals as well as NCSs.

Several ligands, such as alkylthiols, -amines, -silanes, -phosphines, -halides, and simple alkanes, were employed for digestive ripening, a process in which a colloidal suspension in a solvent is refluxed at the solvent boiling temperature in the presence of a surface-active ligand to convert a highly polydisperse colloid into a nearly monodisperse one. Apart from thiols, which are the only established digestive-ripening ligands, amines, silanes, and phosphines were found to be similarly efficient for this purpose. The important steps involved in the digestive ripening were identified to be (1) breaking the polydisperse colloid into smaller size particles upon addition of the ligand, (2) isolating this colloid from the reaction side products, and finally (3) heating this isolated colloid in the presence of the ligand to form a nearly monodisperse colloid. The successful ligands could be differentiated from the others based on their effectiveness to perform the different tasks in each step. Namely, they broke the bigger nanoparticles into smaller ones in the first step, formed a stable redispersable colloid in toluene after the second step, and at the end of the third step lead to a nearly monodisperse colloid. The ability of the different ligands to break the bigger, prismatic as-prepared particles in the first step varied as RSH ≈ RNH2 ≈ R3P ≈ RSiH3 > RI > ROH ≈ RBr and simple alkanes completely failed to induce any changes in the size and shape of the as-prepared colloid. Ligands such as RI, RBr, and ROH failed in the second step, possibly because of the poor ligand−gold interaction. The ligand−gold interaction trends observed here could be rationalized semiqualitatively by invoking the hard and soft acid and base theory, which suggests that a soft acid-like gold likes to interact with softer bases such as RSH and R3P rather than hard bases such as ROH. After the third step, the sizes of the nearly monodisperse particles depended on the ligand used for digestive ripening and correlated well with the ligand−gold interaction trends.